Free Trial

OrthoPediatrics Corp. (NASDAQ:KIDS) Short Interest Up 13.2% in September

OrthoPediatrics logo with Medical background

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 961,700 shares, a growth of 13.2% from the September 15th total of 849,900 shares. Based on an average trading volume of 179,000 shares, the days-to-cover ratio is currently 5.4 days. Currently, 5.9% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on KIDS shares. Needham & Company LLC reissued a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Friday, September 13th. Truist Financial lowered their price objective on shares of OrthoPediatrics from $34.00 to $28.00 and set a "hold" rating on the stock in a research note on Monday. Finally, JMP Securities reissued a "market outperform" rating and issued a $50.00 price objective on shares of OrthoPediatrics in a report on Friday, September 13th.

Check Out Our Latest Report on OrthoPediatrics

OrthoPediatrics Stock Performance

NASDAQ KIDS traded up $1.08 on Tuesday, hitting $27.03. 220,465 shares of the company traded hands, compared to its average volume of 168,599. The business's 50 day moving average price is $28.45 and its 200-day moving average price is $30.11. OrthoPediatrics has a 52-week low of $23.10 and a 52-week high of $36.23. The company has a current ratio of 4.90, a quick ratio of 1.96 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $644.10 million, a price-to-earnings ratio of -28.16 and a beta of 1.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.08. The business had revenue of $52.80 million during the quarter, compared to analyst estimates of $52.40 million. OrthoPediatrics had a negative net margin of 14.35% and a negative return on equity of 5.44%. Equities analysts expect that OrthoPediatrics will post -0.92 earnings per share for the current year.

Insider Transactions at OrthoPediatrics

In related news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $29.30, for a total transaction of $293,000.00. Following the transaction, the general counsel now owns 77,304 shares in the company, valued at $2,265,007.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 31.80% of the company's stock.

Institutional Investors Weigh In On OrthoPediatrics

Institutional investors have recently bought and sold shares of the business. Quest Partners LLC purchased a new position in shares of OrthoPediatrics in the second quarter valued at about $34,000. EntryPoint Capital LLC lifted its holdings in OrthoPediatrics by 56.9% in the 1st quarter. EntryPoint Capital LLC now owns 2,783 shares of the company's stock worth $81,000 after purchasing an additional 1,009 shares in the last quarter. SG Americas Securities LLC bought a new position in OrthoPediatrics in the 2nd quarter worth approximately $110,000. State Board of Administration of Florida Retirement System purchased a new stake in OrthoPediatrics during the 1st quarter valued at approximately $178,000. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of OrthoPediatrics during the second quarter valued at approximately $203,000. Hedge funds and other institutional investors own 69.05% of the company's stock.

About OrthoPediatrics

(Get Free Report)

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Featured Stories

→ Urgent: This election is rigged (From Porter & Company) (Ad)

Should you invest $1,000 in OrthoPediatrics right now?

Before you consider OrthoPediatrics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.

While OrthoPediatrics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Tesla Stock Rockets 15% Post-Earnings

Tesla Stock Rockets 15% Post-Earnings

Will Tesla's rally continue, or is this the time to lock in gains? See how Thomas Hughes suggests playing the market in this exciting post-earnings period.

Related Videos

Tesla Stock: Profits vs. Price—Is It Time to Sell?
Top Stocks to Buy, Sell, and Hold Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines